ArticleFrontiers in medicine2026
Application of failure mode and effects analysis combined with bundled management measures in reducing ICU-acquired infections.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To systematically evaluate the application value and implementation effectiveness of a Failure Mode and Effects Analysis (FMEA)-based bundled management strategy in the precise prevention and control of hospital-acquired infections (HAIs) in the Intensive Care Unit (ICU) of a specialized oncology hospital. Methods: A single-cohort study with pre-post measurements was conducted in the ICU of a tertiary Grade A specialized oncology hospital. The pre-implementation period included 2,975 patients admitted from January to December 2024, receiving conventional HAI prevention and control measures. The post-implementation period included 1,522 patients admitted from January to June 2025, who received an FMEA-driven bundled management strategy in addition to conventional measures. A multidisciplinary FMEA team identified potential failure modes using the "Man, Machine, Material, Method, Environment, Measurement" framework. Risks were quantified using the Risk Priority Number (RPN = Severity × Occurrence × Detection), and high-risk failure modes (RPN ≥ 80) were targeted with multi-dimensional bundled interventions (e.g., multi-departmental coordination, stratified training, hand hygiene improvement). Outcomes included HAI incidence, device-associated infection rates [Ventilator-Associated Pneumonia (VAP), Central Line-Associated Bloodstream Infection (CLABSI), Catheter-Associated Urinary Tract Infection (CAUTI)], hand hygiene compliance, and environmental cleaning quality. Results: Following the intervention, overall HAI incidence decreased significantly from 2.6% (77 infections in 2,975 patients) to 1.6% (25 infections in 1,522 patients) (χ Conclusion: The FMEA-based bundled management strategy effectively identifies and mitigates high-risk vulnerabilities in ICU HAI prevention and control. It significantly reduces HAI and device-associated infection rates while improving hand hygiene compliance and environmental disinfection quality. This model provides an evidence-based paradigm for precise HAI prevention and control in specialized oncology hospital ICUs and holds high potential for broader clinical application.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.